Ethyl((2-[ethyl(methyl)amino]ethyl))amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Ethyl((2-[ethyl(methyl)amino]ethyl))amine
• 英文别名: N,N'-diethyl-N'-methylethane-1,2-diamine
• 化学式: C₇H₁₈N₂
• 分子量: 130.23
• InChiKey: KEUXZGFIRAKFAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF<br/>[FR] 19-NOR-STÉROÏDES NEUROACTIFS ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：SAGE THERAPEUTICS INC

  公开号：WO2014169836A1

  公开（公告）日：2014-10-23

  Provided herein are 3,3-disubstituted19-nor-steroidal compounds according to Formula(I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions,for example, treatment of sleep disorders, mood disorders,schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders,personality disorders,autism spectrum disorders, pain,traumatic brain injury, vascular diseases,substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus.

  根据以下公式(I)，提供了3,3-二取代19-去甲类固醇化合物及其药物组合物。这些化合物被认为对预防和治疗各种与中枢神经系统相关的疾病有用，例如治疗睡眠障碍、情绪障碍、精神分裂症谱系障碍、记忆和/或认知障碍、运动障碍、人格障碍、自闭症谱系障碍、疼痛、创伤性脑损伤、血管疾病、物质滥用障碍和/或戒断综合征、耳鸣、癫痫持续状态。
• AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE
  申请人：Shen Jianhua

  公开号：US20140171431A1

  公开（公告）日：2014-06-19

  The present invention relates to the field of pharmaceutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) and a preparation method thereof, a pharmaceutical composition with the compounds as active components, and a use of the azole compounds and the pharmaceutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA 2 enzyme activities, wherein each substituent is as defined in the specification.

  本发明涉及制药化学领域，特别是一种由通式（I）、（II）或（III）表示的新型类唑化合物，以及其制备方法，以这些化合物为活性成分的药物组合物，以及在制备用于治疗与Lp-PLA2酶活性相关疾病的药物中使用这些唑化合物和药物组合物的用途，其中每个取代基如规范中定义。
• [EN] COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR L'INHIBITION DU TRANSPORT DE PHOSPHATE
  申请人：ARDELYX INC

  公开号：WO2012006473A1

  公开（公告）日：2012-01-12

  Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  具有磷酸盐转运抑制活性的化合物，更具体地说，披露了对肠道顶膜Na/磷酸盐共转运的抑制剂。这些化合物具有以下结构（I）：包括立体异构体、药用可接受的盐及其前药，其中X、Y和A如本文所定义。还披露了与制备和使用这类化合物相关的方法，以及包含这类化合物的药物组合物。
• [EN] ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'ARGININE MÉTHYLTRANSFÉRASE ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2016044585A1

  公开（公告）日：2016-03-24

  Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

  本文描述了公式（I）的化合物，其药学上可接受的盐以及其药物组成物。本文所描述的化合物可用于抑制精氨酸甲基转移酶活性。还描述了使用这些化合物治疗精氨酸甲基转移酶介导的疾病的方法。
• [EN] WATER SOLUBLE THIAZOLYL PEPTIDE DERIVATIVES<br/>[FR] DERIVES DE PEPTIDES DE THIAZOLYL SOLUBLES DANS L'EAU
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2002014354A1

  公开（公告）日：2002-02-21

  Novel thiazolyl peptide compounds useful for the treatment of serious bacterial infections, and pharmaceutical compositions thereof are provided. More particularly, novel thiazolyl peptide compounds are provided having the general formula (I): wherein Q, Y and R1 are as defined in the specification.

  提供了用于治疗严重细菌感染的新型噻唑肽化合物及其制药组合物。更具体地，提供了具有一般式（I）的新型噻唑肽化合物，其中Q、Y和R1如规范中定义。